Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2015

Open Access 01-12-2015 | Research article

Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study

Authors: Halmurat Upur, Yin Chen, Mayila Kamilijiang, Wanli Deng, Xierzhatijiang Sulaiman, Renaguli Aizezi, Xiao Wu, Wuniqiemu Tulake, Abulizi Abudula

Published in: BMC Complementary Medicine and Therapies | Issue 1/2015

Login to get access

Abstract

Background

Traditional Uighur medicine shares an origin with Greco-Arab medicine. It describes the health of a human body as the dynamic homeostasis of four normal Hilits (humours), known as Kan, Phlegm, Safra, and Savda. An abnormal change in one Hilit may cause imbalance among the Hilits, leading to the development of a syndrome. Abnormal Savda is a major syndrome of complex diseases that are associated with common biological changes during disease development. Here, we studied the protein expression profile common to tumour patients with Abnormal Savda to elucidate the biological basis of this syndrome and identify potential biomarkers associated with Abnormal Savda.

Methods

Patients with malignant tumours were classified by the diagnosis of Uighur medicine into two groups: Abnormal Savda type tumour (ASt) and non-Abnormal Savda type tumour (nASt), which includes other syndromes. The profile of proteins that were differentially expressed in ASt compared with nASt and normal controls (NC) was analysed by iTRAQ proteomics and evaluated by bioinformatics using MetaCore™ software and an online database. The expression of candidate proteins was verified in all plasma samples by enzyme-linked immunosorbent assay (ELISA).

Results

We identified 31 plasma proteins that were differentially expressed in ASt compared with nASt, of which only 10 showed quantitatively different expression between ASt and NC. Bioinformatics analysis indicated that most of these proteins are known biomarkers for neoplasms of the stomach, breast, and lung. ELISA detection showed significant upregulation of plasma SAA1 and SPP24 and downregulation of PIGR and FASN in ASt compared with nASt and NC (p < 0.05).

Conclusions

Abnormal Savda may be causally associated with changes in the whole regulation network of protein expression during carcinogenesis. The expression of potential biomarkers might be used to distinguish Abnormal Savda from other syndromes.
Appendix
Available only for authorised users
Literature
1.
David AR, Zimmerman MZ. Cancer: an old disease, a new disease or something in between? Nature Rev Cancer. 2010;10:728–33.CrossRef
2.
Upur H, Dubrovin D, Amat N, Liu W, Moore N, Bauer R, et al. Greco-Arab-Uighur medicine. USA: Acupress; 2013.
3.
Upur H, Yusufu A, Aimaiti N. New interpretations of abnormal savda theory of traditional Uighur medicine. China, Urumqi: Xinjiang People’s Press; 2009.
4.
Halmurat U, Askar Y, Ilhamjan S, Obul K, Roxangul S. Gene polymorphisms in Uighur patients with abnormal savda. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003;20:77–8.PubMed
5.
Tursun K, Asmtula D, Smayil M, Upur D, Upur H. The relationship between asthma patients with abnormal savda in Uighur medicine and the gene polymorphism of IL-4. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33:1076–80.PubMed
6.
Yusup A, Abla A, Upur H. Association study of gene polymorphisms and depression with abnormal humor in traditional Uighur medicine. BMC Complement Altern Med. 2013;13:332. doi:10.1186/1472-6882-13-332.CrossRefPubMedPubMedCentral
7.
Yin P, Mohemaiti P, Chen J, Zhao X, Lu X, Yimiti A, et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871:322–7.CrossRefPubMed
8.
Mamtimin B, Upur H, Hao FH, Matsidik A, Rahim R. Plasma metabonomic analysis with 1H nuclear magnetic resonance revealing the relationship of different tumours and the disease homology theory of traditional Uighur medicine. Chin J Integr Med. 2011;17:111–5.CrossRefPubMed
9.
Batur M, Halmurat U, Hao FH, Aiziz R, Aynur M. Correlative analysis of neoplasm patients with phlegm-stasis or abnormal savda syndrome based on metabonomics. J Tradit Chin Med. 2012;32:119–24.CrossRefPubMed
10.
Abdureyim S, Amat N, Umar A, Upur H, Berke B, Moore N. Anti-inflammatory, immunomodulatory, and heme oxygenase-1 inhibitory activities of ravan napas, a formulation of Uighur traditional medicine, in a rat model of allergic asthma. Evid Based Complement Alternat Med. 2011;2011:pii:725926. doi:10.1155/2011/725926.CrossRef
11.
Ablimit A, Kühnel H, Strasser A, Upur H. Abnormal Savda syndrome: long-term consequences of emotional and physical stress on endocrine and immune activities in an animal model. Chin J Integr Med. 2013;19:603–9.CrossRefPubMed
12.
Upur H, Yusup A, Umar A, Moore N. Uighur traditional medicine syndrome of abnormal savda in men is associated with oxidative stress, which can be improved by Munziq and Mushil of abnormal savda. Therapie. 2004;59:483–4.CrossRefPubMed
13.
Renaguli A, Shajida A, Upur A. Study on classification of complex diseases in Uygur medicine and its prethrombotic state. Chin J Inform TCM. 2009;16:23–5.
14.
Upur H, Dubrovin D, Amat N. Letter to the editor: Avicenna’s view on the prevention of thrombosis. Int J Cardiol. 2013;168:577–8.CrossRefPubMed
15.
Upur H, Maitisidike A, Feidasiyefu, Aimaiti A, Yiming Y, Dubrovin D. Diagnosis of abnormal humor syndrome in traditional Uighur medicine and its prescriptions and herbs. China, Urumqi: Xinjiang People’s Press; 2013.
16.
Amat N, Upur H, Ablimit A, Matsidik A, Yusup A, Kijjoa A. Immunomodulatory effects of abnormal savda Munziq, a traditional Uighur medicine, on the combined stress mice. J Ethnopharmacol. 2009;122:42–7.CrossRefPubMed
17.
Amat N, Hoxur P, Ming D, Matsidik A, Kijjoa A, Upur H. Behavioral, neurochemical and neuroendocrine effects of abnormal savda munziq in the chronic stress mice. Evid Based Complement Alternat Med. 2012;2012:426757. doi:10.1155/2012/426757.CrossRefPubMedPubMedCentral
18.
Yusup A, Upur H, Umar A, Berke B, Yimit D, Lapham JC, et al. Abnormal savda munziq, an herbal preparation of traditional Uighur medicine, may prevent 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Evid Based Complement Alternat Med. 2011;2011:152015. doi:10.1093/ecam/nep059.CrossRefPubMedPubMedCentral
19.
Aikemu A, Umar A, Yusup A, Upur H, Berké B, Bégaud B, et al. Immunomodulatory and antitumour effects of abnormal savda munziq on S180 tumour-bearing mice. BMC Complement Altern Med. 2012;12:157. doi:10.1186/1472-6882-12-157.CrossRefPubMedPubMedCentral
20.
Aikemu A, Yusup A, Umar A, Berké B, Moore N, Upur H. The impact of the Uighur medicine abnormal savda munziq on antitumour and antioxidant activity in a S180 and Ehrlich ascites carcinoma mouse tumour model. Pharmacogn Mag. 2012;8:141–8.CrossRefPubMedPubMedCentral
21.
Yusup A, Upur H, Umar A, Moore N. Protective effects of Munziq and Mushil of abnormal savda to mitochondrial oxidative damage. Fundam Clin Pharmacol. 2004;18:471–6.CrossRefPubMed
22.
Zhang YX, Abliz G, Ye WJ, Mutalipu Z, Li XW, Wang HQ, et al. Mechanisms of hela cell apoptosis induced by abnormal savda munziq total phenolics combined with chemotherapeutic agents. Asian Pac J Cancer Prev. 2014;15:743–7.CrossRefPubMed
23.
Upur H, Yusup A, Baudrimont I, Umar A, Berke B, Yimit D, et al. Inhibition of cell growth and cellular protein, DNA and RNA synthesis in human hepatoma (HepG2) cells by ethanol extract of abnormal savda munziq of traditional Uighur medicine. Evid Based Complement Alternat Med. 2011;2011:251424. doi:10.1093/ecam/nen062.CrossRefPubMedPubMedCentral
24.
Yusup A, Upur H, Umar A, Berke B, Moore N. Ethanol extract of abnormal savda munziq, a herbal preparation of traditional Uighur medicine, inhibits caco-2 cells proliferation via cell cycle arrest and apoptosis. Evid Based Complement Alternat Med. 2012;2012:926329. doi:10.1155/2012/926329.CrossRefPubMed
25.
Wang YS, Shen J, Yu JK, Zhang L, Ma JL, You WC, et al. Protein profiles of serum in gastric cancer at a high-risk area by SELDI-TOF mass spectrometry. Zhong hua Yu Fang Yi Xue Za Zhi. 2008;42:677–80.
26.
Ali IU, Xiao Z, Malone W, Smith M, Conrads TP, Veenstra TD, et al. Plasma proteomic profiling: search for lung cancer diagnostic and early detection markers. Oncol Rep. 2006;15:1367–72.PubMed
27.
Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res. 2008;7:1481–9.CrossRefPubMed
28.
Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, et al. Identification of S100A8 and S100A9 as Serological Markers for Colorectal Cancer. J Proteome Res. 2009;8:1368–79.CrossRefPubMed
29.
Lin YW, Lai HC, Lin CY, Chiou JY, Shui HA, Chang CC, et al. Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. Int J Gynecol Cancer. 2006;16:1216–24.CrossRefPubMed
30.
Wang H, Kachman T, Schwartz D. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics. 2005;4:2476–95.CrossRef
31.
Faca VM, Hanash SM. In depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res. 2009;69:728–30.CrossRefPubMedPubMedCentral
32.
Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complement Ther Med. 2012;20:93–9.CrossRefPubMed
33.
34.
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008;7:1780–94.CrossRefPubMedPubMedCentral
35.
Kruse U, Bantscheff M, Drewes G, Hopf C. Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol Cell Proteomics. 2008;7:1887–901.CrossRefPubMed
36.
Zhao H, Wang W, Guo S. Proteomics study on unstable angina pectoris patients with blood stasis syndrome. J Arteriocleriosis. 2008;7:545–8.
37.
Lan M, Yinghong P, Jianxuan R. Effect of the xuefuzhuyv decoction on serum proteome of rat with syndrome of Qi-stagnancy and blood stasis. Chin J Exp Trad Med Formule. 2008;4:24–8.
38.
Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, et al. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer. 2012;131:911–23.CrossRefPubMed
39.
Liu C, Pan C, Shen J, Wang H, Yong L. Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. Oncol Lett. 2012;3:1259–62.PubMedPubMedCentral
40.
Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 2013;105:1871–80.CrossRefPubMedPubMedCentral
41.
Kanoh Y, Abe T, Masuda N, Akahoshi T. Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncol Rep. 2013;29:469–73.PubMed
42.
Ren Y, Wang H, Lu D, Xie X, Chen X, Peng J, et al. Expression of serum amyloid A in uterine cervical cancer. Diagn Pathol. 2014;9:16. doi:10.1186/1746-1596-9-16.CrossRefPubMedPubMedCentral
43.
44.
Moshkovskii SA. Why do cancer cells produce serum amyloid A acute-phase protein? Biochemistry (Mosc). 2012;77:339–41.CrossRef
45.
Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol. 2012;32:335–48.CrossRefPubMed
46.
Tiwari P, Tripathi LP, Nishikawa-Matsumura T, Ahmad S, Song SN, Isobe T, et al. Prediction and experimental validation of a putative non-consensus binding site fortranscription factor STAT3 in serum amyloid A gene promoter. Biochim Biophys Acta. 1830;2013:3650–5.
47.
48.
49.
Ocak S, Pedchenko TV, Chen H, Harris FT, Qian J, Polosukhin V, et al. Loss of polymeric immunoglobulin receptor expression is associated with lung tumourigenesis. Eur Respir J. 2012;39:1171–80.CrossRefPubMed
50.
DeSouza LV, Romaschin AD, Colgan TJ, Siu KW. Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. Anal Chem. 2009;81:3462–70.CrossRefPubMed
51.
Gologan A, Acquafondata M, Dhir R, Sepulveda AR. Polymeric immunoglobulin receptor-negative tumours represent a more aggressive type of adenocarcinomas of distal esophagus and gastroesophageal junction. Arch Pathol Lab Med. 2008;132:1295–301.PubMed
52.
Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumour metastasis of human hepatocellular carcinoma. J Natl Cancer Inst. 2011;103:1696–712.CrossRefPubMedPubMedCentral
53.
Wu X, Qin L, Fako V, Zhang JT. Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments. Adv Biol Regul. 2014;54:214–21.CrossRefPubMed
54.
Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014;20:2279–303.CrossRefPubMedPubMedCentral
55.
56.
Hopperton KE, Duncan RE, Bazinet RP, Archer MC. Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp Cell Res. 2014;320:302–10.CrossRefPubMed
57.
Brochmann EJ, Behnam K, Murray SS. Bone morphogenetic protein-2 activity is regulated by secreted phosphoprotein-24 kd, an extracellular pseudoreceptor, the gene for which maps to a region of the human genome important for bone quality. Metabolism. 2009;58:644–50.CrossRefPubMed
58.
Tian H, Bi X, Li CS, Zhao KW, Brochmann EJ, Montgomery SR, et al. Secreted phosphoprotein 24 kD (Spp24) and Spp14 affect tgf-β induced bone formation differently. PLoS One. 2013;8:e72645. doi:10.1371/journal.pone.0072645.CrossRefPubMedPubMedCentral
59.
Lee KB, Murray SS, Duarte ME, Spitz JF, Johnson JS, Song KJ, et al. Effects of the bone morphogenetic protein binding protein spp24 (secreted phosphoprotein 24kD) on the growth of human lung cancer cells. J Orthop Res. 2011;29:1712–8.CrossRefPubMed
60.
Eckert JK, Kim YJ, Kim JI, Gürtler K, Oh DY, Sur S, et al. The crystal structure of lipopolysaccharide binding protein reveals the location of a frequent mutation that impairs innate immunity. Immunity. 2013;39:647–60.CrossRefPubMed
61.
Carrouel F, Staquet MJ, Keller JF, Baudouin C, Msika P, Bleicher F, et al. Lipopolysaccharide-binding protein inhibits toll-like receptor 2 activation by lipoteichoic acid in human odontoblast-like cells. J Endod. 2013;39:1008–14.CrossRefPubMed
62.
Resovi A, Pinessi D, Chiorino G, Taraboletti G. Current understanding of the thrombospondin-1 interactome. Matrix Biol. 2014;pii: S0945-053X(14):00023–7.
63.
Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease1. J Surg Res. 2004;122:135–42.CrossRefPubMed
64.
Miyata Y, Sakai H. Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects. Int J Mol Sci. 2013;14:12249–72.CrossRefPubMedPubMedCentral
65.
Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M, et al. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol. 2013;15:897–902.CrossRefPubMed
66.
Suh EJ, Kabir MH, Kang UB, Lee JW, Yu J, Noh DY, et al. Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. Exp Mol Med. 2012;44:36–44.CrossRefPubMed
67.
Lin XD, Chen SQ, Qi YL, Zhu JW, Tang Y, Lin JY. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumour growth and nodal metastasis in gastric carcinoma. J Surg Oncol. 2012;106:94–100.CrossRefPubMed
68.
Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res. 2002;108:51–60.CrossRefPubMed
69.
Schadler KL, Crosby EJ, Zhou AY, Bhang DH, Braunstein L, Baek KH, et al. Immunosurveillance by antiangiogenesis: tumour growth arrest by T cell-derivedthrombospondin-1. Cancer Res. 2014;74:2171–81.CrossRefPubMedPubMedCentral
70.
Upur H, Deng W, Sulaiman X, Tulake W, Wu X, Yuemaier R, Aizezi R, Amat N, and Abudula A. Plasma proteins as potential targets of Abnormal Savda Munziq and Mushil for clinical therapy of malignant tumour patients with Abnormal Savda syndrome of Uighur medicine. In Press
Metadata
Title
Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study
Authors
Halmurat Upur
Yin Chen
Mayila Kamilijiang
Wanli Deng
Xierzhatijiang Sulaiman
Renaguli Aizezi
Xiao Wu
Wuniqiemu Tulake
Abulizi Abudula
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2015
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-015-0526-6

Other articles of this Issue 1/2015

BMC Complementary Medicine and Therapies 1/2015 Go to the issue

Research article

Study of the protective effect on intestinal mucosa of the hydrosoluble fiber Plantago ovata husk

Debate

STRICTA: is it time to do more?

Research article

Proanthocyanidins polymeric tannin from Stryphnodendron adstringens are active against Candida albicans biofilms

Research article

Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin-induced diabetic rats

Research article

Evaluation of antitumor property of extracts and steroidal alkaloids from the cultivated Bulbus Fritillariae ussuriensis and preliminary investigation of its mechanism of action

Research article

Antinociceptive effect of methanol extract of leaves of Persicaria hydropiper in mice